^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
177Lu-PSMA-R2
i
Other names: 177Lu-PSMA-R2, Lu177-PSMA-R2, lutetium-177 PSMA-R2, 177Lu-PSMA-SR6, AAA 602, AAA602, AAA-602
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Novartis
Drug class:
Beta radiation emitter, PSMA inhibitor
Related drugs:
3ms
NeoPSMA: Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC (clinicaltrials.gov)
P1/2, N=228, Not yet recruiting, Novartis Pharmaceuticals | Initiation date: Jun 2025 --> Jun 2026
Trial initiation date
|
177Lu-PSMA-R2
7ms
PROter: 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=27, Terminated, Advanced Accelerator Applications | Phase classification: P1/2 --> P1
Phase classification
|
177Lu-PSMA-R2
9ms
NeoPSMA: Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC (clinicaltrials.gov)
P1/2, N=228, Not yet recruiting, Novartis Pharmaceuticals
New P1/2 trial
|
177Lu-PSMA-R2
over4years
PROter: 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer (clinicaltrials.gov)
P1/2, N=96, Recruiting, Advanced Accelerator Applications | Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
Clinical • Trial completion date • Trial primary completion date
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
177Lu-PSMA-R2
Share via
